Company Served as Sponsor and Provided Operational Leadership for Study Conducted in Partnership with TGen and Virta ...

A new cohort study suggests that Medicaid expansion is associated with a lower mortality risk among patients with pancreatic ...

The MarketWatch News Department was not involved in the creation of this content. Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News ...

Virta Health, the leader in reversing metabolic disease, announced today results from a randomized, controlled Phase II ...

Add Yahoo as a preferred source to see more of our stories on Google. Cancer remains one of humanity's most formidable challenges, claiming the lives of millions every year despite decades of medical ...

(RTTNews) - Immuneering Corporation (IMRX) announced that it will present updated 12-month overall survival data from its ongoing Phase 2a trial of Atebimetinib in combination with modified ...

Pancreatic cancer survival has finally doubled in a decade to 13 percent, a fragile but real sign that years of slow, methodical progress are beginning to add up. November is Pancreatic Cancer ...

A triple drug approach that blocks the KRAS pathway at three points eliminated pancreatic tumors and prevented resistance in ...

A new study of patients who underwent curative surgical removal of a pancreatic ductal adenocarcinoma showed that two of the nine preoperative factors analyzed were strongly predictive of poor ...

Researchers found that treating precancerous pancreatic lesions with experimental KRAS inhibitors slowed tumor development ...

Virta Health, the leader in reversing metabolic disease, announced today results from a randomized, controlled Phase II clinical trial (RCT), offering an early signal that could reshape how advanced ...